Posts with tag Rare Diseases

Essetifin S.p.A., Leadiant Biosciences Ltd., Leadiant GmbH and Sigma – Tau Arzenmittel GmbH (“Leadiant”) were recently sanctioned by the Italian Competition Authority (“ICA”) after investigations revealed an abuse of dominant position in the national market of the sale and production of a pharmaceutical product made of chenodeoxycholic acid (“CDCA”). CDCA is an active ingredient widely used to cure cerebrotendinous xanthomatosis (“CTX”), an ultra-rare disease. According to the ICA,...